Jeffrey Todd, MD
Family Medicine · Woodbury, TNNPI 1700823713
Payments from drug & device makers
Across 130 payments — averaging $19.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$485
- Novo Nordisk$466
- Sanofi-aventis U.S. LLC$265
- Pfizer$234
- Lilly USA, LLC$174
- Novartis$167
- plus $728 from 16 others
What the payments were for
- Food & beverage$2,519100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 18 | $485 |
| Novo Nordisk | 29 | $466 |
| Sanofi-aventis U.S. LLC | 17 | $265 |
| Pfizer | 13 | $234 |
| Lilly USA, LLC | 11 | $174 |
| Novartis | 10 | $167 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $87 |
| Astellas Pharma US Inc | 5 | $84 |
| Axsome Therapeutics, Inc. | 1 | $79 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $73 |
| Ultragenyx Pharmaceutical Inc. | 1 | $70 |
| Johnson & Johnson | 3 | $64 |
| Amgen | 3 | $58 |
| GSK | 3 | $46 |
| AstraZeneca | 3 | $44 |
| Corcept Therapeutics | 1 | $24 |
| Xeris Pharmaceuticals, Inc. | 1 | $21 |
| Sunovion Pharmaceuticals Inc. | 1 | $19 |
| Arbor Pharmaceuticals, Inc. | 1 | $18 |
| Dexcom, Inc. | 1 | $17 |
| Sumitomo Pharma America, Inc. | 1 | $13 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
How this compares
$2,519 in reported general payments places this provider in the 70th percentile of 2,087 family medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 55 | $80,432 |
| EliquisApixaban | 45 | $53,802 |
| OzempicSemaglutide | 38 | $40,974 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 38 | $38,618 |
| MounjaroTirzepatide | 27 | $34,300 |
| RybelsusSemaglutide | 17 | $30,518 |
| LinzessLinaclotide | 48 | $28,743 |
| XareltoRivaroxaban | 31 | $25,010 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 20 | $23,257 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 69 | $21,967 |
| FarxigaDapagliflozin Propanediol | 24 | $21,090 |
| ViberziEluxadoline | 12 | $17,703 |
| JanuviaSitagliptin Phosphate | 58 | $14,416 |
| Tresiba Flextouch U-100Insulin Degludec | 15 | $12,976 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 15 | $12,183 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $174 | $114,73282 claims |
| PfizerEliquis, Abrysvo | $234 | $75,769114 claims |
| Novo NordiskOzempic, Rybelsus | $466 | $71,49255 claims |
| AbbVieLinzess, Viberzi, Synthroid | $485 | $47,91790 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Shingrix | $46 | $32,96177 claims |
| Johnson & JohnsonXarelto | $64 | $25,01031 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $265 | $23,25720 claims |
| AstraZenecaFarxiga | $44 | $21,09024 claims |
| Astellas Pharma US IncMyrbetriq | $84 | $10,68618 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,087 family medicine providers in Tennessee.
Other family medicine in Woodbury
- Rickey ManningKnoxville$8.1M
- Kymberly MoyerGallatin$5.9M
- Natasha BallardChattanooga$5.7M
- Hina BudhwaniNashville$4.7M
- Paul WakefieldKnoxville$4.3M
- Emily HubbsKingsport$2.8M
- Jerry PunchKnoxville$2.1M
- Bridgette FraneyNashville$2M
- Andrew BrockmyreBristol$1.8M
- Marcus LeeTullahoma$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.